Valerio Therapeutics Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting
Seasoned biotech leader with deep expertise in RNA medicines, targeted delivery, and in vivo cell therapy joins to drive Valerio’s next phase of innovation in precision targeted therapeutics
Gilles Besin, Ph.D., appointed Chief Executive Officer effective 1 July 2026, as part of a planned governance transition, bringing a proven track record of building and scaling biotechnology companies through major value-creating milestones directly aligned with the Company's strategic roadmap
Approval by the shareholders’ general meeting of [all] resolutions recommended by the Board of Directors
Regulatory News:
